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Summary The calcium antagonist verapamil (a mixture of D- and L-racemers) is a potent modulator of the
multi-drug resistance phenotype in vitro at a concentration of 6gM. Clinical studies have shown dose-limiting
toxicity of hypotension and heart block when plasma levels approach the concentrations active in vitro.
Previous data indicate that the D-isomer is less cardioactive than the L-isomer but they appear to be
equipotent in reversing drug resistance in vitro. In an attempt to increase plasma verapamil concentrations, we
have treated ten patients (total of 27 courses) with oral D-verapamil (DVPM), 150-300 mg 6 h, and
doxorubicin i.v. 70 mg m2 q 3 weeks. Hypotension (supine systolic BP < 100 mmHg or a fall in systolic BP of
>30 mmHg) occurred in 5/6 patients at 1200 mg day DVPM, in 1/5 at 800 mg day, and in 1/5 at 600 mg day.
PQ prolongation (>0.23 s) was demonstrated in 2/5 patients at 800 mg day DVPM. Plasma levels of DVPM
and its active metabolite norverapamil were measured and, combining these, levels of 3-4gM were achieved at
1200 mg day DVPM; however this dose is likely to lead to unacceptable toxicity in the outpatient setting.
Using an oral outpatient schedule of administration, an appropriate dose of DVPM is 800 mgday. This
provides a combined plasma level (for VPM and DVPM) of 2-3 ILM. If DVPM is to prove useful as a
resistance modulator, it may require to be administered intravenously with careful inpatient monitoring and
support.
Resistance to cytotoxic agents is a common cause of failure
of therapy in both solid tumours and haematological malig-
nancies and there is evidence that expression of the multi-
drug resistance (MDR) phenotype underlies drug resistance
in some tumours (Goldstein et al., 1989). Although several
years have elapsed since the observation that verapamil
reduces resistance to vincristine and doxorubicin in certain
cell lines (Tsuruo et al., 1982), its role in clinical oncology is
still uncertain. The modulation of drug resistance by vera-
pamil appears independent of calcium channel blockage
(Gruber et al., 1988) and is at least in part due to its binding
to the P170 glycoprotein with reduction of drug efflux from
cells via this energy dependent pump (Chen et al., 1986;
Moscow et al., 1988). In vitro studies show a dose response
relationship with maximal reduction of resistance with 6 gM
verapamil (Plumb et al., 1990) but clinical experience of
verapamil in combination with chemotherapy has shown that
plasma verapamil levels of 6 lM and above are associated
with hypotension and heart block (Ozols et al., 1987; Dalton
et al., 1989) and therefore necessitate treatment in an inten-
sive therapy unit.
P-glycoprotein is present in normal tissues and it is possi-
ble that the combination of a modulator of drug efflux and a
cytotoxic agent might increase normal tissue damage. There
is evidence of such enhanced damage when normal bone
marrow stem cells are treated in vitro with verapamil and
doxorubicin (Nakarai et al., 1990), but preclinical in vivo
studies have been inconclusive (Formelli et al., 1988). Clearly
a randomised clinical trial comparing cytotoxic treatment
with and without a modulator of MDR is required to deter-
mine whether such modulation improves treatment outcome
or produces more toxicity. High dose verapamil therapy with
intensive support is not feasible for such a study, which
should preferably comprise outpatient therapy.
Verapamil is usually prescribed as a racemic mixture but
the pharmacological properties of its isomers are quite differ-
ent. L-verapamil is ten times more cardioactive as measured
by PR prolongation and is less protein bound to albumin
(L-88%, D-93%) (Echizen et al., 1985). The isomers are
however equipotent as modulators of drug resistance in vitro
(Tsuruo et al., 1982; Plumb et al., 1990). Predicting that the
reduced cardioactivity of the d-isomer would allow safe
elevation of the plasma level of verapamil towards the target
6liM, we undertook a phase I study of DVPM in combina-
tion with doxorubicin. Our aims were to establish the maxi-
mum tolerated dose of DVPM in this combination in an
outpatient setting, to define dose-limiting toxicity, and to
study the pharmacokinetics of DVPM.
Materials and methods
DVPM was supplied by Knoll AG (Ludwigshafen, Ger-
many). A preliminary single dose study was undertaken in
eight healthy normotensive volunteers; the first four received
placebo, 240 mg racemic verapamil, and 250 mg and 500 mg
DVPM, in random order at weekly intervals; the second four
were treated similarly but with 500 and 1000 mg DVPM.
Similar falls in blood pressure and prolongation of PQ inter-
val were observed with 500 mg DVPM and 240 mg racemic
verapamil. While 500 mg DVPM was well tolerated, 1,000
mg DVPM produced symptomatic hypotension and epigas-
tric discomfort. Pharmacokinetic modelling using data
obtained from these single dose studies suggested that oral
DVPM, 300 mg given 6 h, would achieve plasma verapamil
levels of about 4 tLM (unpublished observations, P. Meredith).
We selected for study patients with advanced or metastatic
gastric, colorectal, or renal carcinoma as these tumours can
have high levels of MDR1 mRNA without prior exposure to
chemotherapy (Goldstein et al., 1989). Each patient had an
Eastern Cooperative Oncology Group (ECOG) performnance
status of two or better. A minimum of 8 weeks had elapsed
since prior chemotherapy and no patients had previously
received anthracyclines. Other criteria for inclusion were:
baseline total white cell count >4 x I09Il, platelets
> 100 x 1091-l, normal serum bilirubin, and other liver
function tests less than twice the upper normal limit. All
patients had normal electrocardiograms with PQ intervals
<0.2 s, heart rate >50 beats per min, resting systolic BP
> 110 mmHg, and a normal pretreatment echocardiogram;
patients with a history of cardiovascular disease were exclud-
ed from the study. Written informed consent was obtained
from each patient according to the dictates of the local
ethical committee. Pretreatment evaluation included a history
and physical examination with documentation of measurable
disease when appropriate.
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Oral DVPM was taken 6 h for 3 days prior to doxorubicin
and continued for a further seven doses after chemotherapy.
ECGs were recorded prior to and 2 h after a dose of DVPM
on the 1st and 4th days of treatment and doxorubicin 70 mg
m 2 given by bolus i.v. injection on the 4th days of DVPM.
Treatment was repeated every 3 weeks. Blood pressure and
pulse rate were monitored in hospital on days 1 and 4 but
patients remained at home for the rest of the study. Toxicity
was charted using standard WHO criteria. Hypotension was
defined as supine systolic BP<1O00 mmHg or a fall in systo-
lic BP of > 30 mmHg. PQ prolongation was defined as PQ
interval >0.23 s. Patients were to be withdrawn from the
study if there was evidence of disease progression, grade 3 or
4 toxicity, unpredictable and life-threatening toxicity, or if
the patient refused further treatment. Patients experiencing
cardiovascular toxicity as defined above were subsequently
treated at a reduced dose of DVPM; patients with myelosup-
pression ofgrade 3 or 4 were allowed to continue on study at
the discretion of the clinician with a reduction in the dose of
doxorubicin to 50mgm2. Blood samples for DVPM phar-
macokinetics were taken at 2, 3, 4, 6, 8, 9 and 10 h after the
first dose of DVPM on the 4th day. Verapamil and norvera-
pamil levels were measured by a sensitive and specific HPLC
method with fluorescent detection (Cole et al., 1981); the
assay does not differentiate between the D- and L- isomers.
The intra-assay and the inter-assay coefficients of variation
were less than 5% for both verapamil and norverapamil. The
limit of detection of the assay was 2 ngml-' using a 100 la
plasma sample.
Results
Ten patients were entered into the study and received a total
fo 27 courses of treatment. Their details are summarised in
Table I and the pattern of toxicity is shown in Table II. The
starting dose of DVPM was chosen on the basis of the
normal volunteer study. The first six patients entered the
study at a daily dose of 1200 mg DVPM but 5/6 developed
hypotension (supine systolic BP < 100 mmHg and/or a drop
in systolic BP > 30 mmHg) during the first or second course
of DVPM and three continued on study at 800 mg day
DVPM. Two additional patients were entered at 800 mg day.
PQ prolongation (>0.23 s) was not seen at 1200 mg day
DVPM but did occur in 2/5 patients receiving 800 mgday.
Hypotension was observed in 1/5 at 800 mg day and the
three patients with toxicity at this dose received further
DVPM at 600 mg day. Two additional patients were entered
at this dose but one became hypotensive during the first
course. Three patients at 1200 mg day with hypotension were
symptomatic, but none at 800 mg and 600 mg. All cardiovas-
cular toxicity reversed spontaneously on cessation of DVPM
and no specific pressor therapy was required to raise blood
pressure.
Gastro-intestinal toxicity was frequent but mild: nausea
and vomiting grade 0 in 2/10, grade 1 in 4/10 and grade 2 in
4/10 patients; and oral mucositis grade 0 in 4/10, grade 1 in
2/10, grade 2 in 3/10, and grade 3 in 1/10 patients. Myelotox-
icity of grade 3 or 4 occurred in 4/10 patients, leading to
subsequent reduction of the doxorubicin dose to 50 mg m2
in two patients.
One patient with gastric cancer and a large paraaortic
node mass had a partial response, documented on CT scan,
of 8 months duration. No other evidence of response was
documented.
Table I Summary of patient details
Number of patients
Age (years) Median
Range
Sex Male
Female
Performance status
(ECOG)
Primary tumour
Extent of disease
Number of courses Median
Range
10
49
44-62
3
7
0-4 patients
1-6 patients
3 stomach
4 colon or rectum
2 adenocarcinoma of unknown
primary
1 kidney
6 hepatic metastases
1 inoperable primary
1 pulmonary and paraaortic
lymphadenopathy
1 peritoneal metastases
1 post-gastrectomy node positive
3
1-5
Plasma levels of both verapamil and norverapamil showed
considerable inter-patient variation (Figure la and b) and
patients who developed hypotension tended to have higher
peak plasma DVPM levels than patients who remained
normotensive (P = 0.04, Mann Whitney U-test) (Figure 2).
When the parent compound and active metabolite (Merry et
al., 1989) levels are combined, levels of 3-4ylM are achieved
at a daily dose of 1200 mg DVPM.
Discussion
The target plasma level of verapamil predicted by in vitro
studies of resistance modulation is 6gM and we have observ-
ed cardiovascular toxicity at half this level with DVPM.
Although the volunteer study showed equivalent cardiovas-
cular activity with 500 mg DVPM and 240 mg racemic vera-
pamil, DVPM drug has shown more cardiovascular toxicity
than predicted (Echizen et al., 1985) and we cannot ade-
quately explain this. It is known that verapamil can inhibit
its own hepatic clearance but the plasma levels measured in
patients at 1200 mgday were actually lower than predicted
from the volunteer study. A possible explanation would be in
vivo alteration of chirality but there is no evidence of this in
single dose studies of DVPM (Vogelgesang et al., 1984); a
chiral assay for verapamil has not yet been developed. It
appears unlikely that levels of 6gM will be achieved safely in
outpatient treatment regimens including DVPM as a resis-
tance modulator although this may not be the case if DVPM
is used on an inpatient basis with careful supervision and
perhaps pressor support. Certainly DVPM is less cardioactive
than racemic VPM and should be the preferred agent if high
plasma concentrations of verapamil are sought.
The relevance of 6 LiM plasma levels to modulation of drug
resistance in clinical practice remains speculative. As yet we
do not know how levels of verapamil achieved in tumour in
vivo relate to plasma concentrations; nor do we know what
VPM concentration in tumour is necessary to modulate clin-
ical multi-drug resistance. Given the extent ofprotein binding
of verapamil it is difficult to know what relationship exists
between the concentration of verapamil active in vitro and
Table II Pattern of toxicity observed at each dose level of DVPM
ArT -L- _A r . r.-- ,- _ t _% . __ Hypotension (systolic
BP < 100 mmHg or
fall of >30 mmHe
Myelotoxicity
WHO Grade
0 1 2 3 4
Nausea and vomiting
WHO Grade
0 1 2 3
vumber
of
patients
Dose
DVPM
(mg day)
Number
of
courses
PQ
prolongation
(>0.23 s)
6 1200 9 0 5 1 140 3 1 2 0 5 0 1
5 800 8 2 1 0 12 11 0 3 20 22 1
5 600 10 0 1 01 0 13 2 3 00 1 12
Oral mucositis
WHO Grade
0 1 2 3
0
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Figure 1 a, Plasma concentration-time profile for DVPM. Bar
denotes mean value; whisker denotes standard error of the mean.
Unfilled bar 1200 mgday n=8; diagonal hatch bar 800mg day
n = 5, speckled hatch bar 600 mg day n = 4. Verapamil admini-
stered at 6 am and 12 noon. b, Plasma concentration-time profile
for sum of verapamil and norverapamil concentrations. Bar
denotes mean value; whisker denotes standard error of the mean.
Unfilled bar 1200mgday n = 8; diagonal hatch bar 800mg day
n = 5, speckled hatch bar 600 mg day n = 4.
that achievable in plasma. Nevertheless it is likely that there
are a series of equilibrium reactions which relate verapamil
concentration in vitro and in vivo to the concentration of
drug at its molecular site of action. Therefore the concept of
target plasma concentration remains useful and may help
with dose escalation and perhaps influence decisions on tak-
ing the schedule forward into phase II trials. A large number
of drugs have now been identified which can modify the
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Figure 2 Peak plasma verapamil concentration related to hypo-
tension. Group 1 denotes courses associated with normal blood
pressure. Group 2 denotes courses associated with hypotension;
pharmacokinetic data for 17 courses.
MDR phenotype in vitro and for some, such as quinidine
(Tsuruo et al., 1984), target plasma levels predicted from
tissue culture data are both achievable and non-toxic.
We were concerned that DVPM might enhance doxoru-
bicin toxicity either by inhibition of drug efflux from normal
cells or through a pharmacokinetic interaction (Kerr et al.,
1986), probably inhibition of hepatic monooxygenase.
Although it has been shown that DVPM undergoes less
extensive first pass metabolism that the L-isomer (Vogelge-
sang et al., 1984), it is not clear whether the pharmacokinetic
interaction with doxorubicin is stereoselective. Although the
observed levels of myelotoxicity and mucositis do not differ
from the expected toxicity for single agent doxorubicin at
this dose, it will be necessary to define the effect of DVPM
on the disposition and metabolism of doxorubicin if DVPM
is taken further as a resistance modulator.
In conclusion, we found that DVPM at 1200 mg daily for
5 days was associated with significant cardiovascular toxicity
(symptomatic hypotension), whereas 800 mg and 600 mg
daily were well tolerated in combination with doxorubicin
(70 mgm-2, 3 weekly) in an outpatient setting. The peak
plasma levels of verapamil (1.89 ± 0.71 ILM) and norvera-
pamil (1.77 ± 0.60S1M) at an appropriate dose (800 mg daily
for 5 days) for large scale phase II outpatient studies are
considerably less than the target plasma concentration of
6jLM. Other studies, using DVPM in hospitalised patients,
may define a higher dose level for use under careful super-
vision.
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